ABL1 and myeloproliferative neoplasm: This implication is supported by another investigation, which clarified that JAK2V617F mutations occur decades before BCR::ABL1-negative MPN diagnosis, increase the fitness of HSCs, and induce a megakaryocyte–erythroid differentiation bias [67].